金輪天地(01232.HK)優先票據昨日到期後退市
金輪天地(01232.HK)發公告澄清,3月10日公告中所述退市,僅針對目前在聯交所上市的2022年到期的12.95%優先票據,公司在聯交所上市地位不會受到影響,公司的運營也不會受到影響。又稱,2022年到期的12.95%優先票據於昨日到期日後在聯交所票據退市。在建議重組事項和開曼計劃成功後,公司將註銷現有票據(包括2022年到期的12.95%優先票據)並發行新票據。該新票據預計會於新加坡交易所上市。
公司稱,對現有票據能夠根據建議重組事項和開曼計劃進行成功重組充滿信心。在建議重組事項和開曼計劃生效後,可對現有票據到期日進行延期三年,會大大緩解和減輕公司的償債壓力,改善整體財務狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.